Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/166339
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome Strategies for In Vivo Administration: Part-II
Journal Title
Director/Tutor
Additional contribution
Journal ISSN
Volume Title
Abstract
Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
Related resource
Subject (English)
Citation
Citation
VIEIRA, Raquel, et al. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome Strategies for In Vivo Administration: Part-II. Journal of Clinical Medicine. 2019. Vol. 8, num. 9, pags. 1332. ISSN 2077-0383. [consulted: 17 of October of 2026]. Available at: https://hdl.handle.net/2445/166339